Enar Recalde Vizcay
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Enar Recalde Vizcay has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Abraham André Arturo Geng Cahuayme
Radiotherapy Oncology Department, Vall d’Hebron Hospital Universitari/Vall d’Hebron Institute of Oncology (VHIO), 08035 Barcelona, Spain
2 shared publications - Alexandra Giraldo
Radiation Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain
2 shared publications - Xavier Maldonado
Department of Radiation Oncology, Hospital Universitari de la Vall d’Hebron, Barcelona, Spain
2 shared publications Begoña Navalpotro Yagüe
Department of Radiation Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
1 shared publicationBlanca Peregrin Pastor
Department of Radiation Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
1 shared publication- Blanca Peregrín-Pastor
Department of Radiation Oncology, Vall d’Hebron University Hospital, Barcelona, Spain
1 shared publication
Latest Publications
- Open Access
- 31 July 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (1) , 366-373
Merkel cell carcinoma: long-term outcomes after radiotherapy treatment
Background: Merkel cell carcinoma (MCC) is a rare, aggressive disease with high relapse and fatality rates. Radiotherapy (RT) is essential for local control, but published data on both initial treatment and relapse management remain limited. Material and methods: We retrospectively analyzed 17 patients treated in a single-center with radical and adjuvant RT. Results: After a mean follow-up of 44 months, five (29%) patients relapsed (mean time to relapse 5.8 months after RT). Four relapses were locoregional, occurring outside the RT field, and received local salvatge therapy. One relapse was distant. Three patients received up to three consecutive RT courses for locoregional progression without systemic therapy. Five (29%) patients died after a mean time of 35.2 months, four of them with active disease. Two deaths were due to disease progression. Conclusions: Despite optimal local treatment, relapse remains common and is linked to poor outcomes, such as distant progression and death. Our findings reinforce the need for close postoperative monitoring and early initiation of adjuvant RT. Outcomes after early relapse suggest a potential role for treatment intensification.
- 31 July 2025
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 28 (1) , 366-373
Open AccessMerkel cell carcinoma: long-term outcomes after radiotherapy treatment
Background: Merkel cell carcinoma (MCC) is a rare, aggressive disease with high relapse and fatality rates. Radiotherapy (RT) is essential for local control, but published data on both initial treatment and relapse management remain limited. Material and methods: We retrospectively analyzed 17 patients treated in a single-center with radical and adjuvant RT. Results: After a mean follow-up of 44 months, five (29%) patients relapsed (mean time to relapse 5.8 months after RT). Four relapses were locoregional, occurring outside the RT field, and received local salvatge therapy. One relapse was distant. Three patients received up to three consecutive RT courses for locoregional progression without systemic therapy. Five (29%) patients died after a mean time of 35.2 months, four of them with active disease. Two deaths were due to disease progression. Conclusions: Despite optimal local treatment, relapse remains common and is linked to poor outcomes, such as distant progression and death. Our findings reinforce the need for close postoperative monitoring and early initiation of adjuvant RT. Outcomes after early relapse suggest a potential role for treatment intensification.
- 13 June 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (12) , 3246-3251
Stereotactic ablative radiotherapy (SABR) for patients with lung tumor and severe pulmonary function impairment
Purpose To evaluate clinical outcomes after SABR in a cohort of early-stage non-small cell lung cancer (NSCLC) or pulmonary metastases in chronic obstructive pulmonary disease (COPD) patients with forced expiratory volume in the first second predicted (FEV1) ≤ 50%. Methods Retrospective single-center study was performed to analyze clinical outcomes and toxicities in COPD patients with severe lung dysfunction treated with SABR from 1st June 2015 to 31st October 2022. Results Thirty four patients (forty locations) were enrolled for analysis. Median follow-up was 2.9 years. Median age was 73.5 years (range, 65.6–80.1). FEV1 was 38% (range, 28.2–50.0) prior to radiotherapy. Median overall survival (OS) was 41.1 months (95% CI 38.9—not reached). OS rates at 2-, 3-, and 5- years were 79%, 71%, and 36%, respectively. Cancer-specific survival rates at 2-, 3-, and 5- years were 96%, 96%, and 68%, respectively. Local control rates at 2-, 3-, and 5- years were 88%, 83%, and 83%, respectively. No grade 4 or 5 toxicity was observed. The most common acute toxicity was pneumonitis (38.2%), of which only 1 patient (2.9%) reported grade 3 acute toxicity. Conclusions Lung SABR in patients with poor pulmonary function may be effective with acceptable toxicity.
- 13 June 2024
- Published by Springer Nature in Clinical and Translational Oncology
- Vol. 26 (12) , 3246-3251
Stereotactic ablative radiotherapy (SABR) for patients with lung tumor and severe pulmonary function impairment
Purpose To evaluate clinical outcomes after SABR in a cohort of early-stage non-small cell lung cancer (NSCLC) or pulmonary metastases in chronic obstructive pulmonary disease (COPD) patients with forced expiratory volume in the first second predicted (FEV1) ≤ 50%. Methods Retrospective single-center study was performed to analyze clinical outcomes and toxicities in COPD patients with severe lung dysfunction treated with SABR from 1st June 2015 to 31st October 2022. Results Thirty four patients (forty locations) were enrolled for analysis. Median follow-up was 2.9 years. Median age was 73.5 years (range, 65.6–80.1). FEV1 was 38% (range, 28.2–50.0) prior to radiotherapy. Median overall survival (OS) was 41.1 months (95% CI 38.9—not reached). OS rates at 2-, 3-, and 5- years were 79%, 71%, and 36%, respectively. Cancer-specific survival rates at 2-, 3-, and 5- years were 96%, 96%, and 68%, respectively. Local control rates at 2-, 3-, and 5- years were 88%, 83%, and 83%, respectively. No grade 4 or 5 toxicity was observed. The most common acute toxicity was pneumonitis (38.2%), of which only 1 patient (2.9%) reported grade 3 acute toxicity. Conclusions Lung SABR in patients with poor pulmonary function may be effective with acceptable toxicity.
- Open Access
- 1 January 2023
- Published by Knowledge Enterprise Journals in Medical Research Archives
- Vol. 11 (6)
Evaluation of Pulmonary Functions by Spirometry after Stereotactic Body Radiotherapy in Lung Tumors
Introduction: To evaluate changes in pulmonary function by spirometry after stereotactic body radiotherapy (SBRT). Methods: A single-center, retrospective study was performed which analyzed lung function after SBRT from January 1, 2015 to January 31, 2020. Eligible patients were ≥18 years of age, with early-stage lung cancer or lung metastases ≤5 cm and Karnofsky performance status (KPS) >70. Patients were excluded if they had a history of non-infectious pneumonitis or interstitial lung disease. Clinical cases were discussed in a multidisciplinary tumor board, and the patients were classified as surgically resectable but medically inoperable. Mixed-effects models were used to evaluate changes in forced expiratory volume in 1 (FEV1), forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) at 3, 6, 12, and 24 months after SBRT. Results: Fifty-two patients underwent SBRT. Median follow-up spirometry post-SBRT was 12 months (range, 12-24). No significant differences were observed during the first year in both liters and the percentage of predicted FEV1 evolution. A gain of 5.9% [95% CI, 2.3; 9.6 percent (p=0.0014)] was beheld after 24 months post-SBRT. Although, no significant difference has been viewed when we analyze it in liters with an FEV1 value 24 months post-SBRT of 1.57 liters [95% CI, 1.56; 1.59 liters (p=0.848)]. There are no differences when we analyze FVC evolution according to liters during the first two years post treatment. Finally, no differences were observed when analyzing DLCO evolution according to percentage or as ml/min/kPa. Conclusions: SBRT in primary lung tumors or pulmonary metastases does not negatively influence pulmonary function assessed by spirometry at least in the first two years after treatment.
- 1 January 2023
- Published by Knowledge Enterprise Journals in Medical Research Archives
- Vol. 11 (6)
Open AccessEvaluation of Pulmonary Functions by Spirometry after Stereotactic Body Radiotherapy in Lung Tumors
Introduction: To evaluate changes in pulmonary function by spirometry after stereotactic body radiotherapy (SBRT). Methods: A single-center, retrospective study was performed which analyzed lung function after SBRT from January 1, 2015 to January 31, 2020. Eligible patients were ≥18 years of age, with early-stage lung cancer or lung metastases ≤5 cm and Karnofsky performance status (KPS) >70. Patients were excluded if they had a history of non-infectious pneumonitis or interstitial lung disease. Clinical cases were discussed in a multidisciplinary tumor board, and the patients were classified as surgically resectable but medically inoperable. Mixed-effects models were used to evaluate changes in forced expiratory volume in 1 (FEV1), forced vital capacity (FVC) and diffusing capacity of the lungs for carbon monoxide (DLCO) at 3, 6, 12, and 24 months after SBRT. Results: Fifty-two patients underwent SBRT. Median follow-up spirometry post-SBRT was 12 months (range, 12-24). No significant differences were observed during the first year in both liters and the percentage of predicted FEV1 evolution. A gain of 5.9% [95% CI, 2.3; 9.6 percent (p=0.0014)] was beheld after 24 months post-SBRT. Although, no significant difference has been viewed when we analyze it in liters with an FEV1 value 24 months post-SBRT of 1.57 liters [95% CI, 1.56; 1.59 liters (p=0.848)]. There are no differences when we analyze FVC evolution according to liters during the first two years post treatment. Finally, no differences were observed when analyzing DLCO evolution according to percentage or as ml/min/kPa. Conclusions: SBRT in primary lung tumors or pulmonary metastases does not negatively influence pulmonary function assessed by spirometry at least in the first two years after treatment.